ArticleScientific reports2026
Risk factors for barrett's esophagus identified in a large-scale Japanese community cohort study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Barrett’s esophagus (BE) is a well-established precursor to esophageal adenocarcinoma (EAC); however, population-based data from East Asia remain limited. Identifying region-specific risk factors for BE is essential for guiding early detection and surveillance strategies. We aimed to estimate the incidence of BE and identify the demographic, clinical, lifestyle, and pharmacologic factors independently associated with BE in a large Japanese cohort. We conducted a retrospective cohort study using a comprehensive administrative database integrating health insurance claims, demographic information, and annual health checkup records. Individuals enrolled in municipal health insurance programs between April 1, 2012, and September 30, 2021, with ≥ 12 months of continuous coverage and no prior BE diagnosis were included. Incident BE was defined as ICD-10 code K22.7 in claims data. Cox proportional hazards models were applied to estimate hazard ratios for incident BE, adjusting for age, sex, comorbidities, lifestyle factors, anatomical conditions (gastroesophageal reflux disease [GERD] and esophageal hiatal hernia [EHH]), Helicobacter pylori (H. pylori) infection, and proton pump inhibitor (PPI) or potassium-competitive acid blocker (P-CAB) and histamine-2 receptor antagonist (H2RA) use. Among 620,125 eligible individuals (median follow-up: 6.2 years), 1,577 incident cases of BE were identified, yielding an incidence rate of 46.4 per 100,000 person-years (95% confidence interval: 44.2–48.7). Independent risk factors included age 50–79 years, male sex, gastroesophageal reflux disease (GERD), esophageal hiatal hernia, peripheral vascular disease, liver disease, and acid-suppressant use. History of H. pylori infection was significant in the model including GERD. In contrast, lifestyle factors including body mass index, diabetes, current smoking, and heavy drinking were not significantly associated with BE in multivariable analysis. The associations with H. pylori infection and PPI/P-CAB. use may reflect reverse causality and should thus be interpreted with caution. These results emphasize the importance of region-specific risk assessment, and support targeted endoscopic surveillance for BE; however, given the inability to account for segment length and the predominance of short-segment BE in Japan, the implications for detecting long-segment BE or EAC remain to be established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.